• We created our antibody-drug conjugate (ADC) technology to achieve better therapies for people with cancer. It is used in Roche's Kadcyla®, which is making a difference for people today.

    Learn More
  • Our work changes us - enabling us to use our special skills and expertise to achieve new therapies for people with cancer.

    Learn More
  • A growing number of compounds with our technology are being evaluated in the clinic to treat many different types of cancer.

    Learn More

News & Events

FORWARD I and FORWARD II clinical trials of mirvetuximab soravtansine are open for enrollment.

Read More

Data reported at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Read More

Encouraging clinical data reported at World Conference on Lung Cancer with anetumab ravtansine (BAY 94-9343) in mesothelioma.

Read More

ImmunoGen, Inc. one of The Boston Globe's
Top Places to Work - recognized for third
consecutive year

Read More

Top Places to Work

Clinical Trials

Clinical trials can provide an opportunity for appropriate patients to receive experimental therapies. Several trials with ImmunoGen ADCs are currently enrolling patients.

Learn More

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue